Atherosclerosis (journal)
Atherosclerosis is a medical journal that focuses on the study of atherosclerosis, a disease in which plaque builds up inside your arteries. The journal publishes original research articles, reviews, and editorials on all aspects of atherosclerosis, including its pathogenesis, epidemiology, clinical diagnosis, treatment, and prevention.
Overview[edit | edit source]
The Atherosclerosis journal was first published in 1969 and is currently published by Elsevier. The journal is affiliated with the European Atherosclerosis Society and the International Atherosclerosis Society. It is indexed in the PubMed database and the Science Citation Index. The journal's impact factor for 2019 was 4.25.
Scope[edit | edit source]
The Atherosclerosis journal covers a wide range of topics related to atherosclerosis. These include, but are not limited to, the molecular biology of atherosclerosis, genetic and environmental risk factors, the role of lipids and lipoproteins, inflammation, immunology, cell biology, pharmacology, endocrinology, nutrition, surgery, and cardiology.
Editorial Board[edit | edit source]
The Atherosclerosis journal's editorial board is composed of leading experts in the field of atherosclerosis from around the world. The current editor-in-chief is Professor John J.P. Kastelein from the University of Amsterdam, The Netherlands.
Submission and Review Process[edit | edit source]
The Atherosclerosis journal follows a rigorous peer review process to ensure the quality and integrity of the research it publishes. Authors are encouraged to submit their manuscripts online through the journal's submission system. The submitted manuscripts are then reviewed by at least two independent reviewers who are experts in the field.
Access[edit | edit source]
The Atherosclerosis journal offers both subscription-based and open access options for readers. The journal's content is available online through the publisher's website and other digital platforms.
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
